Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population

Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. Two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) have been shown to be insufficient to protect against variants of concern (VOCs), while viral vector vaccines remain protective against the i...

Full description

Bibliographic Details
Main Authors: Nawamin Pinpathomrat, Porntip Intapiboon, Purilap Seepathomnarong, Jomkwan Ongarj, Ratchanon Sophonmanee, Jariya Hengprakop, Smonrapat Surasombatpattana, Supattra Uppanisakorn, Surakameth Mahasirimongkol, Waritta Sawaengdee, Supaporn Phumiamorn, Sompong Sapsutthipas, Chanon Kongkamol, Thammasin Ingviya, Pasuree Sangsupawanich, Sarunyou Chusri
Format: Article
Language:English
Published: Nature Portfolio 2022-05-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-022-00475-z

Internet

https://doi.org/10.1038/s41541-022-00475-z

Similar Items